What Do Analysts Think About Elevance Health (ELV)?

Elevance Health, Inc. (NYSE:ELV) is one of the best affordable healthcare stocks to buy now. Elevance Health, Inc. (NYSE:ELV) was downgraded to Hold from Buy by Deutsche Bank analyst George Hill on December 19. The analyst also brought the price target down to $320 from $332.

However, BofA lifted the price target on the stock to $385 from $370 on December 16, reaffirming a Neutral rating on the shares and telling investors that its higher target exhibits higher peer multiples.

In a separate development, Elevance Health’s (NYSE:ELV) board of directors announced on December 10 the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. The company reported that Schulman would serve on the Audit and Finance Committees and contribute expertise in regulatory strategy, healthcare innovation, and value creation across complex enterprises as a recognized healthcare executive, investor, and governance leader.

Management further stated that the appointment exhibits Elevance Health’s (NYSE:ELV) ongoing board refreshment strategy to ensure independent, diverse, and future-focused leadership aligning with the priorities of its stakeholders and its long-term strategy.

Separately, Elevance Health, Inc. (NYSE:ELV) announced on December 5 the expansion of access of its Virtual Assistant, a digital experience built to help members understand their benefits, access information seamlessly, and find care. The Virtual Assistant is available through the Sydney Health app and Elevance Health–affiliated health plan websites, and uses conversational technology to boost engagement between members and their health plans and simplify healthcare navigation.

Elevance Health, Inc. (NYSE:ELV) is a health company that operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a range of health plans and services, while the CarelonRx segment manages pharmacy services. The Carelon Services segment offers various healthcare-related services by integrating behavioral, physical, pharmacy, and social services.

While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.